In Vivo Characterization of a Novel 𝜸-Secretase Inhibitor SCH 697466 in Rodents and Investigation of Strategies for Managing Notch-Related Side Effects

Table 1

Summary of in vivo studies conducted with SCH 697466.

Group	Species	Duration of dosing	Total # of doses	Post-treatment time*	𝑛/group
Acute Rat	Rat	single dose	1	3 hr	7–8
Acute TgCRND8	Mouse	single dose	1	3 or 6 hr	4–6
Acute Non-transgenic	Mouse	single dose	1	3 hr	7
Time course TgCRND8	Mouse	single dose	1	2, 4, 6, 12, 18 or 24 hr	4-5
6 days b.i.d. TgCRND8	Mouse	6 days 𝑏.𝑖.𝑑^†	11	3 hr	4–9
11 days q.d. Non-transgenic	Mouse	11 days q.d.	11	3 hr	4-5
6 days b.i.d. Non-transgenic	Mouse	6 days 𝑏.𝑖.𝑑^†	11	3 hr	4–7

*Time in between administration of the last (or only) dose and collecting tissues following euthanasia.
^†Five full days of dosing with the final dose given the morning of day 6.